Alternative Data for Karyopharm Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 26 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,855 | Sign up | Sign up | Sign up |
| X Followers | 1,564 | Sign up | Sign up | Sign up |
| X Mentions | 22 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 67 | Sign up | Sign up | Sign up |
| Linkedin Employees | 314 | Sign up | Sign up | Sign up |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $7.90 |
| Target Price | Sign up |
| Volume | 735,911 |
| Market Cap | $161M |
| Year Range | $3.77 - $10.09 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $15 Price TargetFebruary 17 - Benzinga |
|
 |
Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call TranscriptFebruary 12 - SeekingAlpha |
Karyopharm Therapeutics Inc. 2025 Q4 - Results - Earnings Call PresentationFebruary 11 - SeekingAlpha |
|
Karyopharm Therapeutics shares are trading higher. The company reported Q4 financial results and issued FY26 guidance.February 11 - Benzinga |
|
 |
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q4 Revenue Miss and Wider Loss, Stock Falls in Pre-MarketFebruary 11 - ChartMill |
UPDATE: Karyopharm Therapeutics Q4 Adj. EPS $(2.23) Misses $(1.99) EstimateFebruary 11 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 34M | 1.5M | 33M | -102M | -18M | -2.227 |
| Q3 '25 | 44M | 2.1M | 42M | -33M | -23M | -3.820 |
| Q2 '25 | 38M | 1.1M | 37M | -37M | -26M | -4.070 |
| Q1 '25 | 30M | 1.3M | 29M | -23M | -12M | -2.770 |
| Q4 '24 | 31M | 1.3M | 29M | -31M | -20M | -3.600 |
Insider Transactions View All
| Abate Kristin filed to sell 22,063 shares at $9.4. March 3 '26 |
| Rangwala Reshma filed to sell 56,739 shares at $9.4. March 3 '26 |
| Mano Michael filed to sell 93,964 shares at $9.4. March 3 '26 |
| Cheng Sohanya Roshan filed to sell 107,317 shares at $9.4. March 3 '26 |
| Poulton Stuart filed to sell 94,328 shares at $9.4. March 3 '26 |
Similar companies
Read more about Karyopharm Therapeutics (KPTI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Karyopharm Therapeutics
The Market Cap of Karyopharm Therapeutics is $161M.
Currently, the price of one share of Karyopharm Therapeutics stock is $7.90.
The KPTI stock price chart above provides a comprehensive visual representation of Karyopharm Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Karyopharm Therapeutics shares. Our platform offers an up-to-date KPTI stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Karyopharm Therapeutics (KPTI) does not offer dividends to its shareholders. Investors interested in Karyopharm Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Karyopharm Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
